Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electrochemical Acid-Base Transport Limitation Principle for Low Electroactive Analyte Sensing in Wastewater Monitoring.

Environmental science & technology·2024
Same author

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

A Strategy for Fabricating Ultra-Flexible Thermoelectric Films Using Ag<sub>2</sub>Se-Based Ink.

Materials (Basel, Switzerland)·2024
Same author

A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib.

Therapeutic advances in medical oncology·2024
Same author

Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.

Lung cancer (Amsterdam, Netherlands)·2024
Same author

Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance.

NPJ precision oncology·2024

Related Experiment Video

Updated: May 14, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Maintenance Therapy for NSCLC: Consensus and Controversy.

Shun Lu1, Yong-Feng Yu

  • 1Shanghai Lung Cancer Center, Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200030, China.

Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|January 30, 2013
PubMed
Summary

Maintenance therapy shows promise for advanced non-small cell lung cancer (NSCLC). However, more data is needed to establish it as standard care and identify predictors for patient benefit and optimal strategy (continuation vs. switch).

Keywords:
ErlotinibMaintenance therapyNon-small cell lung cancerPemetrexed

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Experiment Videos

Last Updated: May 14, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Area of Science:

  • Oncology
  • Medical Research
  • Clinical Trials

Background:

  • Advanced non-small cell lung cancer (NSCLC) remains a significant clinical challenge with limited curative options.
  • Maintenance therapy represents a promising strategy to prolong disease control in advanced NSCLC.
  • Pemetrexed and erlotinib are approved agents for maintenance chemotherapy, indicating progress in the field.

Purpose of the Study:

  • To review current research on maintenance therapy for advanced NSCLC.
  • To discuss the available evidence regarding the efficacy and role of maintenance strategies.
  • To highlight the need for further research to establish optimal treatment paradigms and predictive biomarkers.

Main Methods:

  • Systematic review of published studies on maintenance therapy in advanced NSCLC.
  • Analysis of clinical trial data evaluating continuation and switch maintenance strategies.
  • Discussion of regulatory approvals and clinical guidelines.

Main Results:

  • Several studies demonstrate the potential benefit of maintenance therapy in prolonging progression-free survival and overall survival.
  • Approved agents like pemetrexed and erlotinib have shown efficacy in specific patient populations.
  • Significant heterogeneity exists in study designs, patient populations, and treatment regimens, complicating direct comparisons.

Conclusions:

  • Maintenance therapy is an evolving treatment approach for advanced NSCLC, offering potential benefits.
  • Further research is crucial to define its standard role, identify predictive factors for treatment response, and determine the preferred strategy (continuation vs. switch).
  • Personalized approaches based on predictive biomarkers are needed to optimize outcomes in advanced NSCLC patients receiving maintenance therapy.